Immune Metabolism Dysregulation and Efficacy to Anti-PD-1 PD-L1 Agents in Non Small Cell Lung Cancer Patients
Recruiting now
Conditions studied: Nsclc
In brief
Prospective, biological, observational study involving the collection and use of samples from patients suffering from NSCLC lung cancer, aimed at comparing the molecular profile related to metabolism among subjects with response or resistance to checkpoint inhibitors immune system (ICI), in order to contribute to define response biomarkers and new molecular pathways as therapeutic targets combine with ICI to overcome resistance.
Key facts
- Study ID
- NCT07637474
- Run by
- Regina Elena Cancer Institute
- People needed
- 150
- Starts
- 2024-07-24
- Expected to finish
- 2026-07-24
- Last updated by the study team
- 2026-06-09
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age > 18 years
- Histological diagnosis of advanced stage NSCLC
- Histotype adenocarcinoma and squamous carcinoma
- ECOG PS <2
- Known PDL-1 stage
- Measurable disease
- Availability of tumor tissue
- No evidence of molecular drivers
- Written informed consent (to the study and data processing)
- For the second cohort in addition to the precedents it is included
- Diagnosis of limited or locally advanced NSCLC deemed resectable
- For the third cohort in addition to the precedents it is included
- patients candidates for surgery for non-small cell lung cancer
You may not qualify if…
- Contraindications to immunotherapy
- Unavailability of tumor tissue
- Histotype with neuroendocrine or mixed component
- For the second cohort
- Contraindication to immunotherapy
- Histotype with neuroendocrine or mixed component
- Locally advanced disease candidate for concomitant chemo-radiotherapy treatment
- For the third cohort
- previously treated patients
Where it is running
- IRCCS National Cancer institute — Rome, Rome, Italy (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.